1333481-05-2

Basic information

• Product Name: (S)-4-(N-(2-(α-D-glucopyranose-6-yl)-2-oxoethyl)formamido)-3-(benzyldisulfanyl)pent-3-enyl 2-(6-methoxynaphthalen-2-yl)propanoate
• Synonyms: (S)-4-(N-(2-(α-D-glucopyranose-6-yl)-2-oxoethyl)formamido)-3-(benzyldisulfanyl)pent-3-enyl 2-(6-methoxynaphthalen-2-yl)propanoate
• CAS NO: 1333481-05-2
• Molecular Weight: 715.843
• Mol File: 1333481-05-2.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: (S)-4-(N-(2-(α-D-glucopyranose-6-yl)-2-oxoethyl)formamido)-3-(benzyldisulfanyl)pent-3-enyl 2-(6-methoxynaphthalen-2-yl)propanoate(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-4-(N-(2-(α-D-glucopyranose-6-yl)-2-oxoethyl)formamido)-3-(benzyldisulfanyl)pent-3-enyl 2-(6-methoxynaphthalen-2-yl)propanoate(1333481-05-2)
• EPA Substance Registry System: (S)-4-(N-(2-(α-D-glucopyranose-6-yl)-2-oxoethyl)formamido)-3-(benzyldisulfanyl)pent-3-enyl 2-(6-methoxynaphthalen-2-yl)propanoate(1333481-05-2)

Safety Data

• Hazardous Substances Data: 1333481-05-2(Hazardous Substances Data)

Upstream product

• 1333480-96-8 (S)-4-(N-(2-tert-butoxy-2-oxoethyl)formamido)-3-(benzyldisulfanyl)pent-3-enyl 2-(6-methoxynaphthalen-2-yl)propanoate 
• 1333481-02-9 (S)-4-(N-(2-(1,2,3,4-tetra-O-trimethylsilyl-α-D-glucopyranosyl)-2-oxoethyl)formamido)-3-(benzyldisulfanyl)pent-3-enyl 2-(6-methoxynaphthalen-2-yl)propanoate 
• 1333480-93-5 tert-butyl 2-(N-(3-(benzyldisulfanyl)-5-hydroxypent-2-en-2-yl)formamido)acetate 
• 1769-00-2 1,2,3,4,6-penta-O-trimethylsilyl-α-D-glucopyranose 

Downstream Products

• 22204-53-1 (2S)-2-(6-methoxy(2-naphthyl))propanoic acid 

Relevant articles and documents

Design, synthesis and biological evaluation of brain-specific glucosyl thiamine disulfide prodrugs of naproxen

Glucosyl derivates exhibited favorable distribution to the brain. However, bidirectional transport of glucose transporter 1 might decrease concentrations of the prodrugs in brain before the release of parent drugs. To overcome this defect, glucosyl thiamine disulfide prodrugs 1a-1c incorporating naproxen were designed and synthesized. Furthermore, prodrug 2 and 3 were also prepared as control. The favorable physicochemical properties of these prodrugs were verified by stability and metabolism studies. Results from the in vivo distribution study indicated that 1a-1c, and 1b in particular, significantly increased the level of naproxen in brain when compared to 2 and 3. The study suggested glucosyl thiamine disulfide was a promising carrier to enhance the brain bioavailability of central nervous system active drugs.